In a 1-year period, 292 patients with a histological diagnosis of colorectal carcinoma
were identified (Table I).
24) Prior to the discovery of SATB2, CDX2 was the most specific marker available, present in 60% to 100% of colorectal carcinomas
but strongly positive in only up to 18% of ovarian mucinous carcinomas.
Majority of the patients (68%) of colorectal carcinoma
encountered in study were of age between 41-70 years with mean age of presentation being 54.
extent and spread in our population.
Carcinoma esophagus was seen even more frequently than gastric and colorectal carcinoma
in Karachi, while it was the first malignancy in Peshawar.
Funkhouser: Trial data showed that no colorectal carcinoma
patient with an activating KRAS mutation has responded to treatment with anti-EGFR antibodies.
Based on the results of several clinical studies, we expect trabedersen to significantly improve the therapeutic outcome not only of patients with pancreatic carcinoma but also of patients suffering from high-grade gliomas, malignant melanoma or colorectal carcinoma
Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma
is one of the commonest neoplasm affecting individuals living in industrialized nations.
Solitary and clinically curable adrenal metastasis from colorectal carcinoma
is very rare.
Biopsies of liver metastases from two patients with colorectal carcinoma
were stained for HA before and after one cycle of treatment with PEGPH20.
In the second part of the study sensitivity to chemotherapy was measured in 25 patients with colorectal carcinoma
(CRC) and responsiveness to mistletoe therapy was measured in 41 breast cancer patients receiving adjuvant mistletoe therapy (1) from the first or (2) from the third cycle.
In the largest review to date of colorectal carcinoma
subtypes, signet-ring cell carcinoma was associated with a 5-year survival rate of 27%, compared with 58% and 63% for mucinous carcinoma and adenocarcinoma, respectively.
Following its introduction into clinical practice over 40 years ago, 5-fluorouracil (5-FU) had been the standard chemotherapeutic agent for treating patients with advanced colorectal carcinoma
These authors continued their line of investigation by showing that tumor-associated K-ras mutations were detectable in the urine of pancreatic and colorectal carcinoma